Table 10.

Infections during the treatment leading to discontinuation or death

Phase of treatment, n	Treatment discontinuation	Death	Infection type (organism, type, resistance, no.)
Phase 1a
31	12	19	Salmonella bacteremia: 1 Group A β hemolytic streptococci: 1 E coli (CRO): 5 Klebsiella pneumoniae (CRO): 7 K pneumoniae (ESBL): 1 Acinetobacter baumannii (ESBL): 2 K pneumoniae (Pansensitive): 2 Pseudomonas aeruginosa (Pansensitive): 2 Enterococcus (ampicillin resistant): 1 Probable fungal pneumonia: 5* Possible fungal pneumonia: 8* Pneumonia (culture negative): 4 Hepatosplenic candidiasis: 2 Candidemia (Candida tropicalis): 3 CMV viremia: 1 Osteomyelitis: 1
Phase 1b
0	0	0	0
Protocol M
3	2	1	Probable fungal pneumonia: 1 Cellulitis: 1 Empyema: 1
Reinduction phase
6	1	5	Nosocomial pneumonia: 1 K pneumoniae (ESBL): 1 E coli (Pansensitive): 2 K pneumoniae (Pansensitive): 1 Shewanella putrefaciens: 1 Probable fungal pneumonia: 1* Candidemia: 1 CMV viremia: 1
Maintenance phase
0	0	0	0

CRO, carbapenem-resistant organism; ESBL, extended spectrum β-lactamase–producing organism.

^*Possible and probable fungal pneumonia was defined as per revised EORTC and MSGRC definitions.³⁸